keyword
MENU ▼
Read by QxMD icon Read
search

Hepatitis C genotype 3

keyword
https://www.readbyqxmd.com/read/29334502/risk-of-hepatitis-b-virus-reactivation-among-patients-treated-with-ledipasvir-sofosbuvir-for-hepatitis-c-virus-infection
#1
Beshoy T Yanny, Nyan L Latt, Sammy Saab, Steven Han, Gina Choi, Jason Kramer, Amandeep K Sahota
BACKGROUND: Direct acting antiviral (DAA) agents are the standard of care for treatment of hepatitis C virus (HCV)-infected individuals. Hepatitis B virus (HBV) reactivation during HCV treatment has been reported, the incidence and clinical outcome remains unclear. The aim of our study is to examine the risk of HBV reactivation in actively infected or previously exposed patients during or after HCV treatment with DAAs. METHODS: Adults with chronic HCV infection previously exposed or actively infected with HBV and treated with DAAs between December 2015 to 2016 were included...
January 12, 2018: Journal of Clinical Gastroenterology
https://www.readbyqxmd.com/read/29327401/daclatasvir-and-reduced-dose-sofosbuvir-an-effective-and-pangenotypic-treatment-for-hepatitis-c-in-patients-with-egfr-30-ml-min
#2
Amit Goel, Dharmendra Singh Bhadauria, Anupma Kaul, Prashant Verma, Mayank Mehrotra, Amit Gupta, Raj Kumar Sharma, Praveer Rai, Rakesh Aggarwal
BACKGROUND & AIMS: Sofosbuvir is a key agent for HCV treatment. It is not recommended for patients with chronic kidney disease (CKD) and estimated glomerular filtration rate (eGFR) <30 mL/min. We report real-life experience of treating a cohort of CKD patients with eGFR <30 mL/min using daclatasvir and half-daily dose of sofosbuvir. METHODS: Adults patients who (i) had eGFR<30 ml/min and detectable HCV RNA and (ii) were treated with interferon and ribavirin free, DAA based regimens were included...
January 12, 2018: Nephrology
https://www.readbyqxmd.com/read/29321441/diabetes-mellitus-prevents-an-improvement-in-the-serum-albumin-level-during-interferon-free-sofosbuvir-based-therapy-for-chronic-hepatitis-c-patients-a-multi-institutional-joint-study
#3
Akira Kawano, Hirohisa Shigematsu, Koichiro Miki, Yasunori Ichiki, Chie Morita, Kimihiko Yanagita, Kazuhiro Takahashi, Kazufumi Dohmen, Hideyuki Nomura, Hiromi Ishibashi, Shinji Shimoda
Objective Interferon-free regimens of direct-acting antiviral agents have improved the treatment response for chronic hepatitis C virus (HCV) infection, and improvement in the serum albumin level during interferon-free therapy has been reported. The aim of this study was to identify the factors that influence the improvement in the serum albumin level in patients receiving interferon-free antiviral therapy. Methods This retrospective, multicenter study consisted of 471 Japanese patients with chronic hepatitis and compensated liver cirrhosis infected with HCV who completed 12-week interferon-free sofosbuvir (SOF)-based therapy (SOF plus ledipasvir for genotype 1 [n=276] and SOF with ribavirin for genotype 2 [n=195])...
January 11, 2018: Internal Medicine
https://www.readbyqxmd.com/read/29317673/the-epidemiology-of-hepatitis-c-virus-in-iran-systematic-review-and-meta-analyses
#4
Sarwat Mahmud, Vajiheh Akbarzadeh, Laith J Abu-Raddad
The aim of this study was to characterize hepatitis C virus (HCV) epidemiology in Iran and estimate the pooled mean HCV antibody prevalence in different risk populations. We systematically reviewed and synthesized reports of HCV incidence and/or prevalence, as informed by the Cochrane Collaboration Handbook, and reported our findings following the PRISMA guidelines. DerSimonian-Laird random effects meta-analyses were implemented to estimate HCV prevalence in various risk populations. We identified five HCV incidence and 472 HCV prevalence measures...
January 9, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29316039/treatment-of-hcv-infection-in-poland-at-the-beginning-of-the-interferon-free-era-the-epiter-2-study
#5
Robert Flisiak, Dorota Zarębska-Michaluk, Ewa Janczewska, Agnieszka Staniaszek, Andrzej Gietka, Włodzimierz Mazur, Magdalena Tudrujek, Krzysztof Tomasiewicz, Teresa Belica-Wdowik, Barbara Baka-Ćwierz, Dorota Dybowska, Waldemar Halota, Beata Lorenc, Marek Sitko, Aleksander Garlicki, Hanna Berak, Andrzej Horban, Iwona Orłowska, Krzysztof Simon, Łukasz Socha, Marta Wawrzynowicz-Syczewska, Jerzy Jaroszewicz, Zbigniew Deroń, Agnieszka Czauż-Andrzejuk, Jolanta Citko, Rafał Krygier, Anna Piekarska, Łukasz Laurans, Witold Dobracki, Jolanta Białkowska, Olga Tronina, Małgorzata Pawłowska
The aim of the EpiTer-2 study was to analyze patient characteristics and their medication for HCV infection in Poland at the beginning of the interferon-free era. Analysis of data of HCV infected patients treated during the initial period of availability of interferon-free regimens in Poland, who started therapy after 1 July 2015 and had available an efficacy evaluation report before 30 June 2017 was undertaken. A total of 2879 patients with chronic hepatitis C were entered, including 46% with liver cirrhosis...
January 6, 2018: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29314090/development-and-validation-of-lc-ms-ms-method-for-simultaneous-determination-of-sofosbuvir-and-daclatasvir-in-human-plasma-application-to-pharmacokinetic-study
#6
Ola M Abdallah, Ahmed M Abdel-Megied, Amira S Gouda
The first simple and highly sensitive Liquid chromatography-tandem mass spectrometry (LC-MS/MS) bioanalytical method was developed and fully validated for the simultaneous determination of newly discovered antiviral drugs namely, Sofosbuvir (SOF) and Daclatasvir (DAC) in human plasma. Tadalafil (TAD) was used as internal standard (IS). SOF, DAC and TAD (IS) were extracted from plasma using liquid-liquid extraction technique with methyl tert-butyl ether. The chromatographic separation was carried out using ZorbaxSB-C18 column (4...
January 3, 2018: Biomedical Chromatography: BMC
https://www.readbyqxmd.com/read/29311405/worsening-of-serum-lipid-profile-after-direct-acting-antiviral-treatment
#7
Stefano Gitto, Arrigo F G Cicero, Elisabetta Loggi, Marina Giovannini, Fabio Conti, Elena Grandini, Valeria Guarneri, Alessandra Scuteri, Giovanni Vitale, Carmela Cursaro, Claudio Borghi, Pietro Andreone
INTRODUCTION: Host lipid metabolism influences viral replication and lifecycle of hepatitis C virus. Our aim was to evaluate changes in glucose and lipid metabolism of patients with chronic hepatitis C after therapy with direct acting antivirals (DAA). MATERIAL AND METHODS: We considered patients consecutively treated between January and November 2015 recording clinical data at baseline and week 24 of follow-up. Frozen serum samples were used for apolipoprotein A1 (apoA1), apolipoprotein B (apoB) and lipoprotein (a) [Lp(a)]...
December 27, 2017: Annals of Hepatology
https://www.readbyqxmd.com/read/29310928/sofosbuvir-and-velpatasvir-for-hepatitis-c-virus-infection-in-people-with-recent-injection-drug-use-simplify-an-open-label-single-arm-phase-4-multicentre-trial
#8
Jason Grebely, Olav Dalgard, Brian Conway, Evan B Cunningham, Philip Bruggmann, Behzad Hajarizadeh, Janaki Amin, Julie Bruneau, Margaret Hellard, Alain H Litwin, Philippa Marks, Sophie Quiene, Sharmila Siriragavan, Tanya L Applegate, Tracy Swan, Jude Byrne, Melanie Lacalamita, Adrian Dunlop, Gail V Matthews, Jeff Powis, David Shaw, Maria Christine Thurnheer, Martin Weltman, Ian Kronborg, Curtis Cooper, Jordan J Feld, Chris Fraser, John F Dillon, Phillip Read, Ed Gane, Gregory J Dore
BACKGROUND: Despite revised guidelines that no longer exclude people who inject drugs (PWID) from treatment for hepatitis C virus (HCV) infection, many clinicians are reluctant to treat recent PWID. This study aimed to evaluate the efficacy of sofosbuvir and velpatasvir therapy in people with chronic HCV infection and recent injection drug use. METHODS: In this open-label, single-arm phase 4 trial (SIMPLIFY), we recruited participants with recent injection drug use (past 6 months) and chronic HCV genotype 1-6 infection from seven countries (19 sites)...
January 5, 2018: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29306043/safety-and-effectiveness-of-ledipasvir-and-sofosbuvir-with-or-without-ribavirin-in-treatment-experienced-patients-with-genotype-1-hepatitis-c-virus-infection-and-cirrhosis
#9
Joseph K Lim, Ann Marie Liapakis, Mitchell L Shiffman, Anna S Lok, Stefan Zeuzem, Norah A Terrault, James S Park, Charles S Landis, Mohamed Hassan, Joel Gallant, Alexander Kuo, Paul J Pockros, Monika Vainorius, Lucy Akushevich, Larry Michael, Michael W Fried, David R Nelson, Ziv Ben-Ari
BACKGROUND & AIMS: We aimed to evaluate the safety and effectiveness of 12 or 24 weeks treatment with ledipasvir and sofosbuvir, with or without ribavirin, in treatment-experienced patients with hepatitis C virus (HCV) genotype 1 infection and cirrhosis in routine clinical practice. Patients were followed in a multi-center, prospective, observational cohort study (HCV-TARGET). METHODS: We collected data from 667 treatment-experienced adults with chronic genotype 1 HCV infection who began treatment with ledipasvir and sofosbuvir, with or without ribavirin, from 2011 through September 15, 2016, according to the regional standards of care, at academic (n=39) and community (n=18) centers in the United States, Canada, Germany, and Israel...
January 3, 2018: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29305405/real-world-treatment-of-hepatitis-c-with-second-generation-direct-acting-antivirals-initial-results-from-a-multicentre-canadian-retrospective-cohort-of-diverse-patients
#10
Alex I Aspinall, Abdel A Shaheen, Golasa S Kochaksaraei, Breean Haslam, Samuel S Lee, Gisela Macphail, Jeff Kapler, Oscar E Larios, Kelly W Burak, Mark G Swain, Meredith A Borman, Carla S Coffin
BACKGROUND: High hepatitis C cure rates have been observed in registration trials with second-generation direct-acting antivirals. Real-world data also indicate high sustained viral response (SVR) rates. Our objective was to determine real-world SVR rates for patients infected with hepatitis C virus (HCV) who were treated with second-generation direct-acting antivirals in the first 18 months of their availability in Canada. METHODS: Four centres in Calgary contributed their treatment data for a diverse patient population including those who had or had not undergone liver transplantation, those coinfected with HIV and vulnerable populations...
January 5, 2018: CMAJ Open
https://www.readbyqxmd.com/read/29297980/ledipasvir-sofosbuvir-for-treating-japanese-patients-with-chronic-hepatitis-c-virus-genotype-2-infection
#11
Yasuhiro Asahina, Yoshito Itoh, Yoshiyuki Ueno, Yasushi Matsuzaki, Yasuhiro Takikawa, Hiroshi Yatsuhashi, Takuya Genda, Fusao Ikeda, Takuma Matsuda, Hadas Dvory-Sobol, Deyuan Jiang, Benedetta Massetto, Anu O Osinusi, Diana M Brainard, John G McHutchison, Norifumi Kawada, Nobuyuki Enomoto
BACKGROUND & AIMS: Japanese patients with chronic hepatitis C virus (HCV) genotype 2 infection have high rates of sustained virologic response (SVR) following 12 weeks of treatment with the nucleotide polymerase inhibitor sofosbuvir in combination with ribavirin, which was the standard of care at the time this study was undertaken. We assessed the efficacy of 12 weeks of treatment with a ribavirin-free regimen of ledipasvir-sofosbuvir. METHODS: In an open-label, Phase 3 trial we enrolled Japanese patients with chronic HCV genotype 2 infection, with or without compensated cirrhosis...
January 3, 2018: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/29290174/eight-week-outcomes-of-ledipasvir-sofosbuvir-in-noncirrhotic-treatment-naive-patients-with-hepatitis-c-analysis-of-pharmacy-based-data
#12
Jennifer Andres, Stephen Lott, Kamran Qureshi
BACKGROUND: Clinical trials have demonstrated that 8 weeks of ledipasvir and sofosbuvir (LDV/SOF) achieved high rates of sustained virologic response at 12 weeks (SVR12) in patients with hepatitis C viral (HCV) genotype 1 infection. The effectiveness of this combination was noted to be robust in treatment-naive noncirrhotic patients and in patients with an HCV viral load of < 6 million IU/mL before treatment. Generalizability of these results to community clinical practice, however, was advised with caution due to the variability of staging methods, fluctuating nature of viral loads, lack of prospective trials, and real-life confirmation...
January 2018: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29288514/high-efficacy-of-ombitasvir-paritaprevir-ritonavir-plus-dasabuvir-in-hepatitis-c-genotypes-4-and-1-infected-patients-with-severe-chronic-kidney-disease
#13
Faisal M Sanai, Abdullah S Alghamdi, Ahmad A Afghani, Khalid Alswat, Adnan AlZanbagi, Mosfer N Alghamdi, Abdallah AlMousa, Mohammed Aseeri, Abdullah M Assiri, Mohamed A Babatin
Limited data has shown high efficacy of co-formulated ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) in the treatment of hepatitis C virus (HCV) genotype (GT)-4, and combined with dasabuvir (DSV) in GT1 patients, with chronic kidney disease (CKD) stage 4-5 (<30 mL/min/1.73 m2 ). We assessed real-world safety and efficacy of OBV/PTV/r ± DSV in GT1 and 4-infected patients. METHODS: In this observational cohort (n=67), we enrolled stage 4-5 CKD treatment-naïve or Peginterferon/RBV-experienced GT4-infected patients (n=32) treated for 12-24 weeks with OBV/PTV/r ± RBV, and plus DSV in GT1 patients (n=35, including 3 with GT1/4 co-infection)...
December 29, 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/29287014/treatment-of-chronic-hepatitis-c-virus-infection-in-children-a-position-paper-by-the-hepatology-committee-of-european-society-of-paediatric-gastroenterology-hepatology-and-nutrition
#14
Giuseppe Indolfi, Loreto Hierro, Antal Dezsofi, Jörg Jahnel, Dominique Debray, Nedim Hadzic, Piotr Czubowski, Girish Gupte, Yael Mozer-Glassberg, Wendy van der Woerd, Françoise Smets, Henkjan J Verkade, Björn Fischler
OBJECTIVES: In 2017, the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) approved the use of the fixed-dose combination of ledipasvir/sofosbuvir and of the combination of sofosbuvir and ribavirin for treatment of adolescents (12-17 years, weighing more than 35 kg) with chronic hepatitis C virus (HCV) genotype 1, 4, 5 and 6 and genotype 2 and 3 infections, respectively. Although trials with direct acting antivirals (DAAs) are ongoing for younger children, the only available treatment in US and Europe for those < 12 years is still the dual therapy of pegylated interferon (PEG IFN) and ribavirin...
December 28, 2017: Journal of Pediatric Gastroenterology and Nutrition
https://www.readbyqxmd.com/read/29283074/genetic-susceptibility-in-family-members-of-egyptian-hepatitis-c-virus-infected-patients-role-of-interleukin-12-b-gene-polymorphism
#15
Nadia Elwan, Fathia Assal, Asem Elfert, Lobna AboAli, Shaimaa Soliman, Samah Soliman, Walaa Elkhalawany, Rehab Badawy, Laila Effat, Khalda Sayed, Safinaz Shalaby, Marwa Shehab, Mohamed Abdel-Hamid, Sherief Abd-Elsalam
AIM: The research was conducted to study Interleukin (IL)-12B gene polymorphism in families of Hepatitis C virus (HCV) infected patients in Egypt. METHODS: Three hundreds HCV patients, 860 family members and 100 healthy subjects were studied. All family members were screened for HCV antibodies by enzyme-linked immunosorbent assay (ELISA). Positive cases were examined using Real-Time polymerase chain reaction (PCR) to confirm the presence of HCV ribonucleic acid (RNA) and detect the viral load...
December 27, 2017: Infectious Disorders Drug Targets
https://www.readbyqxmd.com/read/29276096/the-association-of-variations-in-tlr-genes-and-spontaneous-immune-control-of-hepatitis-b-virus
#16
Seyma Katrinli, Adil Nigdelioglu, Kamil Ozdil, Gizem Dinler-Doganay, Levent Doganay
BACKGROUND: Toll-like receptors (TLRs) are suspected to play a critical role in liver diseases and the progression of chronic hepatitis B (CHB) infection. In this study, we investigated the possible association between TLRs and hepatitis B virus (HBV) infection chronicity in Turkish population. METHODS: TLR4 (+896 A→G) (rs4986790), TLR5 (+1846 T→C) (rs5744174) and TLR9 (-1237T→C) (rs5743836) polymorphisms were screened in 131 CHB patient and 168 individuals by polymerase chain reaction (PCR) - restriction fragment length polymorphism (RFLP) technique...
December 21, 2017: Clinics and Research in Hepatology and Gastroenterology
https://www.readbyqxmd.com/read/29274184/prevalence-of-mixed-genotype-hepatitis-c-virus-infections-in-the-uk-as-determined-by-genotype-specific-pcr-and-deep-sequencing
#17
A L McNaughton, V B Sreenu, G Wilkie, R Gunson, K Templeton, E C McWilliam Leitch
The incidence of mixed genotype hepatitis C virus infections in the UK is largely unknown. As the efficacy of direct acting antivirals is variable across different genotypes, treatment regimens are tailored to the infecting genotype, which may pose issues for the treatment of underlying genotypes within undiagnosed mixed genotype HCV infections. There is therefore a need to accurately diagnose mixed genotype infections prior to treatment. PCR-based diagnostic tools were developed to screen for the occurrence of mixed genotype infections caused by the most common UK genotypes, 1a and 3, in a cohort of 506 individuals diagnosed with either of these genotypes...
December 23, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29258449/the-rs738409-polymorphism-of-the-pnpla3-gene-is-associated-with-hepatic-steatosis-and-fibrosis-in-brazilian-patients-with-chronic-hepatitis-c
#18
Caroline Manchiero, Arielle Karen da Silva Nunes, Mariana Carvalheiro Magri, Bianca Peixoto Dantas, Celso Carmo Mazza, Antonio Alci Barone, Fátima Mitiko Tengan
BACKGROUND: Prospective studies have shown that 80% of acute hepatitis C virus (HCV) cases progress to chronic infection; approximately 10-20% of patients with these conditions will develop liver cirrhosis within 2 to 3 decades, and 1-5% will develop liver cancer. Some studies have indicated that the rs738409 polymorphism of the PNPLA3 gene is associated with steatosis and the progression of advanced fibrosis. This study assessed the contribution of the PNPLA3 rs738409 polymorphism with regard to the steatosis and degree of liver fibrosis in Brazilian patients diagnosed with chronic hepatitis C...
December 19, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/29250328/sequence-analysis-of-hepatitis-c-virus-nonstructural-protein-3-4a-serine-protease-and-prediction-of-conserved-b-and-t-cell-epitopes
#19
Ayesha Naeem, Yasir Waheed
The hepatitis C virus (HCV) is a global health issue. The nonstructural protein 3 (NS3)-4Agene of HCV is responsible for serine protease activity. The aim of the present study was to develop a global consensus sequence of HCV serine protease, analyze conserved residues, and predict highly conserved B- and T-cell binding epitopes in the NS3-4A protein. A total of 160 NS3-4A sequences from the six genotypes of HCV were refracted in the current study. The amino acid sequences were aligned to obtain a global consensus sequence...
December 2017: Biomedical Reports
https://www.readbyqxmd.com/read/29247579/peg-interferon-and-ribavirin-treatment-in-hiv-hcv-co-infected-patients-in-thailand-efficacy-safety-and-pharmacokinetics
#20
E J Smolders, N Thammajaruk, C T M M de Kanter, A Colbers, P Chaiyahong, T Cuprasitrut, S Chittmittraprap, T Apornpong, S Khemnark, P Tangkijvanich, D M Burger, A Avihingsanon
OBJECTIVE: In Thailand, 7.2% of HIV patients are co-infected with hepatitis C virus (HCV) and these patients are treated with peg-interferon + ribavirin (PR) for their HCV-infection. This study evaluates efficacy and safety of PR treatment and pharmacokinetics of ribavirin in this population. METHODS: HIV/HCV co-infected Thai patients were treated with PR for 24 or 48 weeks. R plasma concentrations were measured during treatment. Sustained virological response 24 weeks after end of treatment (SVR24) was used to describe efficacy...
December 16, 2017: Tropical Medicine & International Health: TM & IH
keyword
keyword
85439
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"